Andexanet alfa-The first 150 days

Am J Hematol. 2019 Jan;94(1):E21-E24. doi: 10.1002/ajh.25326. Epub 2018 Nov 26.

Authors

Sarah E Culbreth¹, Jessica Rimsans¹, Katelyn Sylvester¹, Daniel J Pallin², Jean M Connors³

Affiliations

¹ Department of Pharmacy Services, Brigham and Women's Hospital, Boston, Massachusetts.
² Department of Emergency Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
³ Brigham and Women's Hospital, Department of Medicine, Division of Hematology, Boston, Massachusetts.

PMID: 30358896
DOI: 10.1002/ajh.25326

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Antidotes / therapeutic use*
Factor Xa / therapeutic use*
Factor Xa Inhibitors / adverse effects*
Factor Xa Inhibitors / therapeutic use
Female
Hemorrhage / chemically induced
Hemorrhage / drug therapy*
Humans
Intracranial Hemorrhages / chemically induced
Intracranial Hemorrhages / drug therapy
Male
Postoperative Hemorrhage / chemically induced
Postoperative Hemorrhage / drug therapy
Practice Guidelines as Topic
Pyrazoles / adverse effects
Pyrazoles / therapeutic use
Pyridones / adverse effects
Pyridones / therapeutic use
Recombinant Proteins / therapeutic use*
Rivaroxaban / adverse effects
Rivaroxaban / therapeutic use
Thrombophilia / drug therapy
Thrombosis / prevention & control
Treatment Outcome

Substances

Antidotes
Factor Xa Inhibitors
PRT064445
Pyrazoles
Pyridones
Recombinant Proteins
apixaban
Rivaroxaban
Factor Xa